The impact of chemotherapy on cognitive outcomes in adults with primary brain tumors

Journal of Neuro-Oncology

Volumn 108, Issue 2, 2012, Pages 285-290

  Abrey, Lauren E ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Chemo brain; Chemotherapy; Cognition; Glioblastoma; Oligodendroglioma; Primary brain tumor; Primary CNS lymphoma

Indexed keywords

ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CORTICOSTEROID; METHOTREXATE; TEMOZOLOMIDE;

ADULT; AGE; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVOR; CHEMORADIOTHERAPY; COGNITION; COGNITIVE DEFECT; COMORBIDITY; DEPRESSION; DRUG MEGADOSE; FATIGUE; GLIOBLASTOMA; GLIOMA; HUMAN; INSOMNIA; LEUKOENCEPHALOPATHY; MANIA; MEMORY DISORDER; MOOD CHANGE; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PSYCHOSIS; QUALITY OF LIFE; RADIATION NECROSIS; REVIEW; SEIZURE; SIDE EFFECT; VISUAL DISORDER;

ADULT; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; COGNITION DISORDERS; HUMANS;

EID: 84864056178     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-012-0807-6     Document Type: Review

References (51)

1. Janelsins MC, Kohli S, Mohile SG et al (2011) An update on cancer- and chemotherapy-related cognitive dysfunction: current status. Semin Oncol 38:431-438
2. Wefel JS, Vardy J, Ahles T, Schagen SB (2011) International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 12:703-708
3. Raffa RB, Tallarida RJ (2010) Effects on the visual system might contribute to some of the cognitive deficits of cancer chemotherapy- induced 'chemo-fog'. J Clin Pharm Ther 35:249-255
4. Dietrich J, Han R, Yang Y et al (2006) CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and vivo. J Biol 5:1-23
5. Dietrich J, Monje M, Wefel J et al (2008) Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist 13:1285-1295
6. Saykin AJ, Ahles TA, McDonald BC (2003) Mechanisms of chemotherapy-induced cognitive disorders: neuropsychological, pathophysiological, and neuroimaging perspectives. Semin Clin Neuropsychiatry 8:201-216 (Pubitemid 37474731)
7. Petzold A, Mondria T, Kuhle J et al (2010) Evidence for acute neurotoxicity after chemotherapy. Ann Neurol 68:806-815
8. Lucas MR (2010) The impact of chemo brain on the patient with a high-grade glioma. Adv Exp Med Biol 678:21-25
9. Kaleita TA, Wellisch DK, Cloughesy TF et al (2004) Prediction of neurocognitive outcome in adult brain tumor patients. J Neurooncol 67:245-253 (Pubitemid 38418276)
10. Correa DD (2010) Neurocognitive function in brain tumors. Curr Neurol Neurosci Rep 10:232-239
11. Fietta P, Fietta P, Delsante G (2009) Central nervous system effects of natural and synthetic glucocorticoids. Psychiatry Clin Neurosci 63(5):613-622
12. Baile WF (1996) Neuropsychiatric disorders in cancer patients. Curr Opin Oncol 8(3):182-187 (Pubitemid 26200845)
13. Béhin A, Delattre JY (2004) Complications of radiation therapy on the brain and spinal cord. Semin Neurol 24(4):405-417 (Pubitemid 40076117)
14. Correa DD, Maron L, Harder H et al (2007) Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. Ann Oncol 18:1145-1151 (Pubitemid 47244358)
15. Sandor V, Stark-Vancs V, Pearson D et al (1998) Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol 16:3000-3006 (Pubitemid 28417419)
16. Correa DD, Anderson ND, Glass A et al (2003) Cognitive functions in primary central nervous system lymphoma patients treated with chemotherapy and stem cell transplantation: preliminary findings. Clin Adv Hematol Oncol 1:490
17. Fliessbach K, Urbach H, Helmstaedter C et al (2003) Cognitive performance and magnetic resonance imaging findings after highdose systemic and intraventricular chemotherapy for primary central nervous system lymphoma. Arch Neurol 60:563-568 (Pubitemid 36427970)
18. Fliessbach K, Helmstaedter C, Urbach H et al (2005) Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study. Neurology 64:1184-1188
19. Pels H, Schmidt-Wolf IGH, Glasmacher A et al (2003) Primary central nervous system lymphoma: results of a pilot study and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 21:4489-4495 (Pubitemid 46594018)
20. Schlegel U, Pels H, Glasmacher A et al (2001) Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study. J Neurol Neurosurg Psychiatr 71:118-122
21. Herrlinger U, Kuker W, Uhl M et al (2005) NOA-03 trial of highdose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol 57:843-847 (Pubitemid 40798622)
22. McAllister LD, Doolittle ND, Guastadisegni PE et al (2000) Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 46:51-60
23. Correa DD, DeAngelis LM, Shi W et al (2004) Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 62:548-555 (Pubitemid 38252794)
24. Wick W, Hartmann C, Engel C et al (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27:5874-5880
25. Lassman AB, Iwamoto FM, Cloughesy TF et al (2011) International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol 13:649-659
26. Abrey LE, Childs BH, Paleologos N et al (2006) High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up. Neuro Oncol 8:183-188 (Pubitemid 46542663)
27. A phase III intergroup study of radiotherapy versus temozolomide alone versus radiotherapy with concomitant and adjuvant temozolomide for patients with 1p/19q codeleted anaplastic glioma. ClinicalTrials.gov identifier: NCT00887146
28. Soffietti R, Baumert BG, Bello L (2010) European federation of neurological societies. Guidelines on management of low-grade gliomas: report of an EFNS-EANO task force. Eur J Neurol 17(9):1124-1133
29. Mason WP, Krol GS, DeAngelis LM (1996) Low-grade oligodendroglioma responds to chemotherapy. Neurology 46(1):203- 207 (Pubitemid 26156130)
30. Brada M, Viviers L, Abson C et al (2003) Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 14(12):1715-1721 (Pubitemid 38029041)
31. Kesari S, Schiff D, Drappatz J et al (2009) Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res 15(1):330-337
32. Correa DD, Shi W, Thaler HT et al (2008) Longitudinal cognitive follow-up in low grade gliomas. J Neurooncol 86(3):321-327
33. van den Bent MJ, Wefel JS, Schiff D et al (2011) Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 12(6):583-593
34. A phase III randomized study of radiotherapy versus temozolomide in patients with low-grade gliomas. ClinicalTrials.gov identifier: NCT00182819
35. A phase III study of radiation therapy with or without temozolomide for symptomatic or progressive low-grade gliomas. ClinicalTrials. gov identifier: NCT00978458
36. van den Bent MJ, Carpentier AF, Brandes AA et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715-2722 (Pubitemid 46630567)
37. Cairncross G, Berkey B, Shaw E et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: intergroup radiation therapy oncology group trial 9402. J Clin Oncol 24:2707-2714 (Pubitemid 46630566)
38. Wang M, Cairncross G, Shaw E et al (2010) Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. Int J Radiat Oncol Biol Phys 77:662-669
39. Taphoorn MJ, van den Bent MJ, Mauer ME et al (2007) Healthrelated quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for research and treatment of cancer randomized clinical trial. J Clin Oncol 25:5723-5730
40. Steinbach JP, Blaicher HP, Herrlinger U et al (2006) Surviving glioblastoma for more than 5 years: the patient's perspective. Neurology 66:239-242 (Pubitemid 43970162)
41. Hottinger AF, Yoon H, DeAngelis LM, Abrey LE (2009) Neurological outcome of long-term glioblastoma survivors. J Neurooncol 95:301-305
42. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996 (Pubitemid 40349501)
43. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466
44. Hilverda K, Bosma I, Heimans JJ et al (2010) Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings. J Neurooncol 97:89-94
45. Scott JG, Suh JH, Elson P et al (2011) Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or older: a retrospective review of 206 cases. Neuro Oncol 13:428-436
46. Brandes AA, Franceschi E, Tosoni A et al (2009) Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer 115:3512-3518
47. Minniti G, De Sanctis V, Muni R et al (2008) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol 88:97-103
48. Sijben AE, McIntyre JB, Roldán GB et al (2008) Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme. J Neurooncol 89:97-103
49. A randomized phase III study of temozolomide and short-course radiation versus short-course radiation alone in the treatment of newly diagnosed glioblastoma multiforme in elderly patients. Clinicaltrials.gov identifier: NCT00482677
50. Gállego Pérez-Larraya J, Ducray F, Chinot O et al (2011) Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. J Clin Oncol 29(22):3050-3055
51. Wefel JS, Cloughesy T, Zazzali JL et al (2011) Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol 13:660-668